158 related articles for article (PubMed ID: 10212587)
1. The role of pharmacokinetic and pharmacodynamic studies in the planning of protocols for the treatment of childhood cancer.
Burke GA; Estlin EJ; Lowis SP
Cancer Treat Rev; 1999 Feb; 25(1):13-27. PubMed ID: 10212587
[TBL] [Abstract][Full Text] [Related]
2. Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide.
Estlin EJ; Yule SM; Lowis SP
Cancer Treat Rev; 2001 Dec; 27(6):339-50. PubMed ID: 11908927
[TBL] [Abstract][Full Text] [Related]
3. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
4. Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines.
Ronghe M; Burke GA; Lowis SP; Estlin EJ
Cancer Treat Rev; 2001 Dec; 27(6):327-37. PubMed ID: 11908926
[TBL] [Abstract][Full Text] [Related]
5. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
[TBL] [Abstract][Full Text] [Related]
7. Three decades of chemotherapy for childhood cancer: from cure 'at any cost' to cure 'at least cost'.
Craft AW; Pearson AD
Cancer Surv; 1989; 8(3):605-29. PubMed ID: 2561755
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
[TBL] [Abstract][Full Text] [Related]
9. Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine.
Estlin EJ
Cancer Treat Rev; 2001 Dec; 27(6):351-63. PubMed ID: 11908928
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
11. L-asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia.
Baillargeon J; Langevin AM; Lewis M; Thomas PJ; Mullins J; Dugan J; Pollock BH
Cancer; 2005 Dec; 104(12):2858-61. PubMed ID: 16288492
[TBL] [Abstract][Full Text] [Related]
12. [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
Skoczeń S; Balwierz W; Moryl-Bujakowska A; Pawińska K; Luszczyńska A; Balcerska A; Płoszyńska A; Chybicka A; Dobaczewski G; Juszczak K; Wachowiak J; Derwich K; Kowalczyk J; Wiśniewska-Slusarz H; Matysiak M; Krauze A; Pawelec K; Sońta-Jakimczyk D; Tomaszewska R; Wysocki M; Styczyńskii J; Swiatkiewicz V;
Przegl Lek; 2006; 63(1):11-4. PubMed ID: 16892892
[TBL] [Abstract][Full Text] [Related]
13. Modeling multi-drug chemotherapy: tailoring treatment to individuals.
Gardner SN
J Theor Biol; 2002 Jan; 214(2):181-207. PubMed ID: 11812172
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic studies in children with cancer.
Groninger E; Proost JH; de Graaf SS
Crit Rev Oncol Hematol; 2004 Dec; 52(3):173-97. PubMed ID: 15582785
[TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
16. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
[TBL] [Abstract][Full Text] [Related]
18. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P
Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324
[TBL] [Abstract][Full Text] [Related]
19. Oral mucositis in acute lymphoblastic leukaemia: analysis of 169 paediatric patients.
Figliolia SL; Oliveira DT; Pereira MC; Lauris JR; Maurício AR; Oliveira DT; Mello de Andrea ML
Oral Dis; 2008 Nov; 14(8):761-6. PubMed ID: 18761642
[TBL] [Abstract][Full Text] [Related]
20. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease.
Athale UH; Siciliano SA; Crowther M; Barr RD; Chan AK
Br J Haematol; 2005 Jun; 129(6):803-10. PubMed ID: 15953008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
